Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

NCT04190550 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

NIH

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Interventions

DRUG: Cytarabine
DRUG: Idarubicin Hydrochloride
DRUG: Navtemadlin

Sponsor

National Cancer Institute (NCI)